Open Orphan has successfully raised capital in an oversubscribed fundraise
Open Orphan Plc has completed an equity placing to raise US$15.5 million to maximize available COVID-19 opportunities and testing.
Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Open Orphan comprises of two commercial specialist CRO services businesses: hVIVO and Venn Life Sciences, and has offices in London, Dublin, Paris and the Netherlands. The company is led by a management team with deep industry and financial experience.
Oaklins Cavendish’s sister firm finnCap, based in the UK, advised Open Orphan Plc on its oversubscribed equity fundraising of US$15.5 million.
Talk to the deal team
Related deals
Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
Learn moreBackspin has completed a mandatory public tender offer for the shares of Spindox
Backspin S.p.A. has completed a mandatory public tender offer for Spindox S.p.A.
Learn moreRare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Learn more